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To evaluate efficacy and tolerability of adjunctive lacosamide in children and adolescents with
uncontrolled focal (partial-onset) seizures.
Methods
In this double-blind trial (SP0969; NCT01921205), patients (age ≥4–<17 years) with un-
controlled focal seizures were randomized (1:1) to adjunctive lacosamide/placebo. After a 6-week
titration, patients who reached the target dose range for their weight (<30 kg: 8–12mg/kg/d oral
solution; ≥30–<50 kg: 6–8 mg/kg/d oral solution; ≥50 kg: 300–400 mg/d tablets) entered
a 10-week maintenance period. The primary outcome was change in focal seizure frequency per
28 days from baseline to maintenance.
Results
Three hundred forty-three patients were randomized; 306 (lacosamide 152 of 171 [88.9%];
placebo 154 of 172 [89.5%]) completed treatment (titration andmaintenance). Adverse events
(AEs) were the most common reasons for discontinuation during treatment (lacosamide 4.1%;
placebo 5.8%). From baseline to maintenance, percent reduction in focal seizure frequency per
28 days for lacosamide (n = 170) vs placebo (n = 168) was 31.7% (p = 0.0003). During
maintenance, median percent reduction in focal seizure frequency per 28 days was 51.7% for
lacosamide and 21.7% for placebo. Fifty percent responder rates (≥50% reduction) were 52.9%
and 33.3% (odds ratio 2.17, p = 0.0006). During treatment, treatment-emergent AEs were
reported by 67.8% lacosamide-treated patients (placebo 58.1%), most commonly (≥10%)
somnolence (14.0%, placebo 5.2%) and dizziness (10.5%, placebo 3.5%).
Conclusions
Adjunctive lacosamide was efficacious in reducing seizure frequency and generally well toler-




This trial provides Class I evidence that for children and adolescents with uncontrolled focal
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Approximately 25% to 30% of children with epilepsy have
uncontrolled seizures despite antiepileptic drug (AED)
treatment1; therefore, novel AED therapies are sorely needed.
Lacosamide is an AED that exerts its anticonvulsant activity by
selectively enhancing slow inactivation of voltage-gated so-
dium channels.2 It has a predictable pharmacokinetic profile
with a high oral bioavailability and a low potential for clinically
relevant pharmacokinetic drug-drug interactions.3 Lacosa-
mide is indicated for the treatment of focal (partial-onset)
seizures in patients ≥4 years of age in the United States and
the European Union.
The efficacy, safety, and tolerability of lacosamide as adjunc-
tive therapy and monotherapy for adults with focal seizures
have been demonstrated in several randomized controlled
trials4–9 and are further supported by clinical practice
experience.10–12 The use of adjunctive lacosamide in children
and adolescents has been investigated in open-label trials13,14
and reported in observational studies.15–20 The objective of
this randomized, double-blind, placebo-controlled trial was to
evaluate the efficacy and tolerability of adjunctive lacosamide
in children and adolescents (≥4–<17 years of age) with un-
controlled focal seizures.
Methods
Standard protocol approvals, registrations,
and patient consents
The trial was conducted in accordance with good clinical
practice and the Declaration of Helsinki. The protocol and
amendments were reviewed by a national, regional, or in-
dependent ethics committee or institutional review board.
Each patient (when able to assent) and the parent or legal
guardian provided written informed consent. The trial was
registered with ClinicalTrials.gov (NCT01921205).
Patients
SP0969 was a randomized, double-blind, placebo-controlled
trial conducted at 114 sites in Europe, North America, Latin
America, and the Asia Pacific region. Eligibility criteria were
assessed by the investigators at the screening visit. Children
and adolescents (≥4–<17 years of age) were eligible for en-
rollment if they had a diagnosis of epilepsy with focal (partial-
onset) seizures, with ≥1 prior EEG and MRI/CT scans con-
sistent with this diagnosis. Additional inclusion criteria were
uncontrolled focal seizures after an adequate course of treat-
ment (in the opinion of the investigator) with ≥2 AEDs
(concurrently or sequentially); an average of ≥2 focal seizures
per 28 days, with nomore than 21 days without seizures in the
8-week period before entering the baseline period, and at least
2 focal seizures during the 8-week prospective baseline; and
a stable dose regimen of 1 to 3 AEDs for ≥4 weeks before the
baseline period and throughout the trial. Exclusion criteria
included assignment to lacosamide in a previous trial or par-
ticipation in a trial of another investigational medical product
or device within the previous 2 months; convulsive status
epilepticus (within the previous 2 months); Lennox-Gastaut
syndrome; primary generalized epilepsy; mixed seizure dis-
order (focal [partial] and primarily generalized seizures);
exclusively febrile seizures; nocturnal seizures only; or epi-
lepsy secondary to a progressive cerebral or neurodegenera-
tive disease (additional criteria in supplemental Methods
available from Dryad, doi.org/10.5061/dryad.kt5jj49).
Trial design
The trial consisted of an 8-week prospective baseline period,
16-week treatment period (6-week titration, 10-week main-
tenance), 4-week taper/transition period, and a 30-day safety
follow-up period for patients not entering the open-label ex-
tension trial (EP0034; NCT01964560) (figure 1). Eligible
patients were randomized (1:1) to lacosamide or placebo.
Trial medication was administered orally twice daily at ≈12-
hour intervals. Patients weighing <50 kg initiated lacosamide or
matching placebo at a dose of 2 mg/kg/d (oral solution), and
thoseweighing≥50 kg had a starting dose of 100mg/d (tablets)
(figure 1). Patients weighing ≥50 kg who were unwilling or
unable to swallow tablets took the oral solution. A dosing sy-
ringe was used to ensure accurate administration of the oral
solution. Administration of oral solution by feeding tube was
permitted if needed.
After the first week of treatment, the investigator determined
whether the patient could tolerate a dose increase or should
remain on the current dose. Doses were increased in weekly
increments of 2 mg/kg/d (oral solution; patients weighing
<50 kg) or 100mg/d (tablets; patients weighing ≥50 kg), with
unlimited dose holds and/or back-titration permitted at the
investigator’s discretion. The target dose range for each pa-
tient was based on body weight at baseline: 8 to 12 mg/kg/
d for <30 kg, 6 to 8 mg/kg/d for ≥30 kg to <50 kg, and 300 to
400 mg/d for ≥50 kg. Patients who were not able to reach the
minimum target dose by the end of the 6-week titration pe-
riod were withdrawn. No further dose adjustments were
permitted during the 10-week maintenance period. Patients
who completed the maintenance period had the option of
transitioning to an open-label extension trial or tapering off
their trial medication.
Glossary
AE = adverse event; AED = antiepileptic drug; BRIEF = Behavior Rating Inventory of Executive Function; CBCL = Child
Behavior Checklist; CI = confidence interval; ILAE = International League Against Epilepsy; LS = least squares; MHD =
10-hydroxycarbazepine; SCB = sodium channel–blocking; TEAE = treatment-emergent adverse event.
Neurology.org/N Neurology | Volume 93, Number 12 | September 17, 2019 e1213
Patients attended weekly trial visits throughout the titration
period and fortnightly visits thereafter. Throughout the trial,
patients and/or their caregivers completed a daily diary of
seizure activity (type and frequency). Diaries were checked by
the investigators at each visit to ensure accurate and thorough
completion and were used to assess efficacy outcomes. Per the
trial protocol, seizure types were defined according to the
International League Against Epilepsy (ILAE) 1981 criteria as
simple partial (focal aware according to the ILAE 2017 clas-
sification), complex partial (focal impaired awareness), and
partial evolving to secondarily generalized (focal to bilateral
tonic-clonic).21,22
Outcome variables
The primary efficacy outcome was the change in focal seizure
frequency per 28 days from baseline to maintenance. Sec-
ondary outcomes were the change in focal seizure frequency
per 28 days from baseline to the entire treatment period
(titration and maintenance combined), assessed overall and
by focal (partial) seizure subtype (simple partial, complex
partial, secondarily generalized); patients with a ≥50% re-
duction in focal seizure frequency (50% responders; main-
tenance); patients with a ≥25% increase in focal seizure
frequency per 28 days (treatment); the proportion of
seizure-free days (maintenance); and the proportion of
patients who completed maintenance without a seizure
(achieved seizure-free status). Other efficacy outcomes
(assessed post hoc) were the median percent reduction from
baseline in focal seizure frequency per 28 days (maintenance
and treatment), 50% responders during treatment, and
patients with a ≥75% reduction in focal seizure frequency
(75% responders; maintenance and treatment).
Safety outcomes included the incidences of treatment-
emergent adverse events (TEAEs), discontinuations due to
TEAEs, shifts from baseline to last visit in assessments of
behavior and cognitive function (Achenbach Child Behavior
Checklist [CBCL]; Behavior Rating Inventory of Executive
Function [BRIEF]/BRIEF-Preschool version), clinical labo-
ratory evaluations, ECG and vital sign monitoring, and
physical and neurologic examinations. The time to onset, dose
at onset, and duration of somnolence and dizziness were also
assessed.
Pharmacokinetic outcomes included plasma concentrations
of lacosamide and concomitant AEDs based on blood samples
at the screening visit, final titration and maintenance visits,
and/or early termination visit. Post hoc analyses of pharma-
cokinetic data were performed to evaluate the plasma con-
centrations of concomitant AEDs during adjunctive
lacosamide treatment.
Statistical analyses
Efficacy analyses comprised the full analysis set of all ran-
domized patients who received at least 1 dose of trial medi-
cation and who had a baseline and at least 1 postbaseline
assessment of seizure frequency data. Randomized patients
who received at least 1 dose of trial medication were included
in safety analyses (safety set). Patients who had at least 1
measurable postdose plasma sample (plasma level above the
Figure 1 SP0969 trial design
PBO = placebo. aThe highest possible dose per body weight category is shown for each taper period week. bPatients on lacosamide remained on their
maintenance dose during the transition period, whereas patients in the placebo group initiated lacosamide in a double-blind fashion. On completion of the
transition period, eligible patients entered the open-label extension on a weight-based dose (<30 kg: 10 mg/kg/d; ≥30–<50 kg: 6 mg/kg/d; ≥50 kg: 300 mg/d).
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limit of quantification, with documented sampling and med-
ication intake times) were included in pharmacokinetic
analyses (pharmacokinetic–per-protocol set).
The trial was powered to detect a significant difference from
baseline to maintenance between lacosamide and placebo in
focal seizure frequency per 28 days. One hundred thirty-five
patients per treatment arm were necessary to detect an effect
size of 0.342 (placebo-subtracted difference of −0.249 and
a common SD of 0.73 on the log-transformed data, equivalent
to ≈22% reduction over placebo after exponentiation) with
a power of 80% and a 2-sided test at a significance level of 5%.
With this sample size, a 2-sided continuity-corrected χ2 test at
a significance level of 5% will provide ≈87% power for as-
sessment of the 50% responder rate, assuming responder rates
of 22% and 40% for the placebo and lacosamide groups, re-
spectively. To account for an anticipated dropout rate of
≈14%, 308 patients were planned for enrollment (154 per
treatment arm). During the trial, a blinded re-estimation of
sample size was performed, and the target for randomization
was increased to 340 patients (supplemental Methods avail-
able from Dryad, doi.org/10.5061/dryad.kt5jj49).
Assessments of focal seizure frequency per 28 days were based
on the number of days for which seizure information was
provided during the specified time interval. If >10% of the
diary entries were missing for a specific patient and time in-
terval, then that patient was not included in the analyses of
seizure frequency or seizure-free days during that time in-
terval. For those who discontinued before maintenance, all
available seizure frequency data from the titration period were
carried forward for the maintenance period analysis. Similarly,
for patients who discontinued during maintenance, all avail-
able seizure frequency data were used for the calculation of
seizure frequency per 28 days during the maintenance period.
For the primary outcome, an analysis of covariance was per-
formed on log-transformed seizure frequency with terms for
treatment and pooled center and log-transformed baseline
seizure frequency as a covariate. The change in focal seizure
frequency for lacosamide vs placebo during maintenance was
compared using least squares (LS) means, and the percent
reduction over placebo was estimated. The change in focal
seizure frequency per 28 days during treatment and the pro-
portion of seizure-free days during maintenance (days with no
seizures/days with lacosamide, per patient diary) were ana-
lyzed with similar methods. Responder rates were analyzed
with a logistic regression model with terms for treatment and
pooled center, and odds ratios with 95% confidence intervals
(CIs) were calculated. Patients who discontinued before
maintenance were treated as nonresponders. Descriptive
analyses were performed for all other efficacy and safety
outcomes.
Post hoc subgroup analyses of efficacy outcomes were per-
formed by focal seizure subtype (including the combined
category of complex partial and/or secondarily generalized
seizures) and by concomitant use of sodium channel–
blocking (SCB) AEDs (carbamazepine, lamotrigine, oxcar-
bazepine, phenytoin, and rufinamide). Post hoc subgroup
analyses of TEAE data were performed by number of con-
comitant AEDs, and by concomitant SCB use.
Patients were included in post hoc analyses of plasma levels of
concomitant AEDs if they were on a stable dose regimen of
valproic acid, levetiracetam, lamotrigine, carbamazepine,
topiramate, oxcarbazepine, clonazepam, or clobazam and had
plasma levels above the lower limit of quantification for the
selected AEDs at baseline and at least 1 postbaseline visit
during treatment. For patients on oxcarbazepine, the plasma
concentration of the main oxcarbazepine active metabolite
10-hydroxycarbazepine (MHD) was assessed. Patients who
received >1 concomitant AEDwere counted once within each
AED category. Repeated-measures analysis of covariance was
performed, and geometric LS mean ratios (treatment/
baseline) with 90% CIs were estimated for plasma concen-
trations. No lacosamide effect on AED concentration was
concluded if the 90% CIs of the geometric LS means ratios
were within the bioequivalence limit of 0.8 to 1.25.
Data availability
Underlying data from this manuscript may be requested by
qualified researchers 6 months after product or indication
approval in the US and/or Europe, or global development is
discontinued, and 18 months after trial completion. Inves-
tigators may request access to anonymized individual patient
data and redacted study documents, which may include raw
datasets, analysis-ready datasets, study protocol, blank case
report form, annotated case report form, statistical analysis
plan, dataset specifications, and clinical study report. Before
use of the data, proposals need to be approved by an in-
dependent review panel at www.clinicalstudydatarequest.com
and a signed data sharing agreement will need to be executed.
All documents are available in English only, for a prespecified
time, typically 12 months, on a password-protected portal.
Classification of evidence
Primary research question was the following: is adjunctive
lacosamide efficacious in reducing focal seizure frequency in
children and adolescents with uncontrolled focal seizures?
This trial provides Class 1 evidence that adjunctive lacosa-




The trial was performed between August 2013 and January
2017. Three hundred forty-three patients were randomized,
of whom 306 completed the treatment period and 302
completed the trial (figure 2). Adverse events (AEs) were the
most common reasons for trial discontinuation during
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treatment (lacosamide: 7 [4.1%]; placebo: 10 [5.8%]). One
hundred fifty-one (88.3%) patients on lacosamide and 148
(86.0%) patients on placebo planned to continue to the open-
label extension trial.
Baseline demographic data and epilepsy characteristics were
similar between treatment groups (table 1). The majority of
patients (267 [77.8%]) were white. Patients had a median
epilepsy duration of 6.0 years and a median age at diagnosis of
3.9 years. On the day of first trial dose, the majority of patients
were taking 2 or 3 concomitant AEDs (table 1). Valproate and
levetiracetam were the most common concomitant AEDs.
Most patients (224 [65.3%]) took at least 1 SCB AED.
During titration, most patients (lacosamide: 142 [83.0%];
placebo: 156 [90.7%]) did not require any back-titration
step. The median of the median daily dose of lacosamide
during maintenance was 12 mg/kg/d for patients weighing
<30 kg, 8 mg/kg/d for those weighing ≥30 to <50 kg, and
400 mg/d for those weighing ≥50 kg. One hundred (58.5%)
patients on lacosamide and 161 (93.6%) on placebo reached
the maximum target dose level for their weight. A higher
proportion of lacosamide-treated patients with 1 concomi-
tant AED at baseline (22 of 30 [73.3%]) than those with 2
(45 of 78 [57.7%]) or 3 (33 of 63 [52.4%]) concomitant
AEDs reached their maximum target dose level. The maxi-
mum target lacosamide dose was reached by 38 of 55
(69.1%) patients not on concomitant SCB AEDs and 62 of
116 (53.4%) of those on ≥1 SCB AED.
Efficacy
Three hundred forty patients had postbaseline seizure fre-
quency data and were included in the full analysis set (figure
2). At baseline, the median focal seizure frequency per 28
days was 10.41 for patients randomized to lacosamide and
8.77 for those randomized to placebo (table 2). The percent
reduction for lacosamide vs placebo in focal seizure
frequency per 28 days was 31.72% (p = 0.0003) during
maintenance and 30.18% (p < 0.0001) during treatment
(table 2). The median percent reductions from baseline to
maintenance in focal seizure frequency per 28 days were
51.7% and 21.7% for lacosamide and placebo, respectively
(figure 3). Generally similar responses were observed during
the entire treatment period (figure e-1 available from Dryad,
doi.org/10.5061/dryad.kt5jj49).
The proportions of 50% and 75% responders during the
maintenance period were higher with lacosamide vs placebo
Figure 2 Patient disposition
FAS = full analysis set; PK-PPS = pharmacokinetic–per-protocol set; SS = safety set.
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Table 1 Baseline demographics and epilepsy characteristics (safety set)
Placebo (n = 172) Lacosamide (n = 171) All patients (n = 343)
Patient demographics
Age, mean (SD), y 10.9 (3.5) 10.5 (3.6) 10.7 (3.5)
Male, n (%) 99 (57.6) 91 (53.2) 190 (55.4)
BMI, median (range), kg/m2 18.55 (11.1–55.8)a 18.50 (10.3–38.1)a 18.50 (10.3–55.8)b
Weight band, n (%)
<30 kg 52 (30.2) 61 (35.7) 113 (32.9)
≥30 kg–<50 kg 60 (34.9) 46 (26.9) 106 (30.9)
≥50 kg 60 (34.9) 64 (37.4) 124 (36.2)
Epilepsy history
Age at diagnosis, median (range), y 4.55 (0.0–15.6) 3.59 (0.0–15.2) 3.92 (0.0–15.6)
Epilepsy duration, median (range), y 6.04 (0.4–16.2) 6.00 (0.4–15.7) 6.02 (0.4–16.2)
Classification of seizures experienced at any point before trial entryc,d
Any partial-onset seizures (focal), n (%) 172 (100) 171 (100) 343 (100)
Simple partial (focal aware) 85 (49.4) 94 (55.0) 179 (52.2)
Complex partial (focal impaired awareness) 131 (76.2) 134 (78.4) 265 (77.3)
Partial evolving to secondarily generalized (focal to bilateral tonic-clonic) 104 (60.5) 111 (64.9) 215 (62.7)
Any generalized seizures, n (%) 1 (0.6) 4 (2.3) 5 (1.5)
Absence 1 (0.6) 2 (1.2) 3 (0.9)
Atypical absence 1 (0.6) 0 1 (0.3)
Myoclonic 0 2 (1.2) 2 (0.6)
Unclassified epileptic seizures, n (%) 1 (0.6) 1 (0.6) 2 (0.6)
No. of previous AEDse, n (%)
0 63 (36.6) 47 (27.5) 110 (32.1)
1–3 79 (45.9) 94 (55.0) 173 (50.4)
4–6 24 (14.0) 25 (14.6) 49 (14.3)
≥7 6 (3.5) 5 (2.9) 11 (3.2)
Concomitant AEDsf
No. of concomitant AEDs on day of first trial dose, n (%)
1 29 (16.9) 30 (17.5) 59 (17.2)
2 82 (47.7) 78 (45.6) 160 (46.6)
3 61 (35.5) 63 (36.8) 124 (36.2)
Concomitant AEDs taken by ≥ 10% of overall population, n (%)
Valproateg 86 (50.0) 80 (46.8) 166 (48.4)
Levetiracetam 68 (39.5) 74 (43.3) 142 (41.4)
Carbamazepine 39 (22.7) 50 (29.2) 89 (25.9)
Lamotrigine 41 (23.8) 48 (28.1) 89 (25.9)
Topiramate 43 (25.0) 39 (22.8) 82 (23.9)
Oxcarbazepine 30 (17.4) 23 (13.5) 53 (15.5)
Continued
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(figure 3). The mean proportion of seizure-free days during
maintenance was 0.71 on lacosamide and 0.66 on placebo (LS
mean treatment difference 0.07 (95% CI 0.029–0.115, p =
0.0011). Among patients who completed maintenance, 23 of
152 (15.1%) on lacosamide and 15 of 154 (9.7%) on placebo
were seizure-free. Similar proportions of patients on lacosa-
mide (32 of 170 [18.8%]) and placebo (39 of 169 [23.1%])
had a ≥25% increase from baseline to treatment in focal sei-
zure frequency per 28 days.
Subgroup analyses showed similar efficacy of lacosamide in
patients with and without concomitant SCB AEDs (table 2
and figure 3). Assessments by focal seizure subtype showed
reductions in seizure frequency per 28 days with lacosamide
vs placebo in simple partial (focal aware), complex partial
(focal impaired awareness), and secondarily generalized (fo-
cal to bilateral tonic-clonic) seizures, as well as reductions in
the combined category of complex partial and/or secondarily
generalized seizures (table 2). Higher median percent
reductions from baseline in seizure frequency per 28 days and
higher 50% and 75% responder rates were also observed with
lacosamide vs placebo for these focal seizure subtypes (figure
e-2 available from Dryad, doi.org/10.5061/dryad.kt5jj49).
Safety and tolerability
One hundred sixteen (67.8%) patients on lacosamide and 100
(58.1%) on placebo reported TEAEs during the treatment
period (table 3). As judged by the investigator, these TEAEs
were drug related in 54 (31.6%) patients on lacosamide and
31 (18.0%) on placebo. Most TEAEs were mild or moderate
in intensity; 5 (2.9%) patients on lacosamide and 6 (3.5%) on
placebo reported severe TEAEs. In both treatment groups,
the incidences of TEAEs and drug-related TEAEs were higher
during titration than maintenance (table 3).
In the lacosamide group, somnolence and dizziness were the
most common TEAEs (≥10% of patients) and the most
common drug-related TEAEs (≥5% of patients). Somnolence
was reported by 24 (14.0%) lacosamide-treated patients (34
events) (placebo 9 [5.2%] patients, 12 events) and was con-
sidered to be drug related in 21 (12.3%) patients on
Table 1 Baseline demographics and epilepsy characteristics (safety set) (continued)
Placebo (n = 172) Lacosamide (n = 171) All patients (n = 343)
Any concomitant SCB AEDs, n (%) 108 (62.8) 116 (67.8) 224 (65.3)
Ongoing comorbid conditions at trial entry
Any ongoing medical condition, n (%) 108 (62.8) 105 (61.4) 213 (62.1)
No. of conditions per patient
Mean (SD) 2.2 (4.0) 2.0 (2.7) 2.1 (3.5)
Median (Q1, Q3) 1.0 (0.0, 3.0) 1.0 (0.0, 3.0) 1.0 (0.0, 3.0)
0, n (%) 64 (37.2) 66 (38.6) 130 (37.9)
1, n (%) 36 (20.9) 32 (18.7) 68 (19.8)
2, n (%) 24 (14.0) 21 (12.3) 45 (13.1)
≥3, n (%) 48 (27.9) 52 (30.4) 100 (29.2)
Medical conditions present in ≥5% of overall population, n (%)
Mental retardation 25 (14.5) 22 (12.9) 47 (13.7)
Cerebral palsy 15 (8.7) 20 (11.7) 35 (10.2)
Hemiparesis 11 (6.4) 12 (7.0) 23 (6.7)
Developmental delay 8 (4.7) 9 (5.3) 17 (5.0)
Concomitant non-AED medicationsh
Any concomitant non-AED, n (%) 83 (48.3) 81 (47.4) 164 (47.8)
Abbreviations: AED = antiepileptic drug; BMI = body mass index; Q = quartile; SCB = sodium channel blocker.
a n = 170.
b n = 340.
c Seizure types are listed per the trial protocol (International League Against Epilepsy [ILAE] 1981)21 with the ILAE 2017 classification22 provided in
parentheses.
d Multiple seizure types could be reported.
e AEDs taken and stopped >28 days before entry into the baseline period.
f AEDs taken concomitantly for at least 1 day during the trial period.
g Category includes valproic acid, valproate semisodium, valproate sodium, ergenyl chrono, and valpromide.
h Non-AEDs taken concomitantly for at least 1 day during trial period.
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Table 2 Reduction in focal seizure frequency per 28 days (full analysis set)










Focal seizures, n 168 170 169 170
Baseline seizure frequency per 28 d, median 8.77 10.41 8.69 10.41
Seizure frequency per 28 d during assessed trial period, mediana 8.71 6.36 9.33 6.46
Percent reduction vs placebo (95% CI), p value 31.72 (16.342–44.277); p = 0.0003 30.18 (17.490–40.919); p < 0.0001
Assessments by focal seizure subtype
Simple partial (focal aware), nb 67 77 68 77
Baseline seizure frequency per 28 d, median 5.78 7.50 5.39 7.50
Seizure frequency per 28 d during assessed trial period, mediana 4.67 3.11 5.75 4.71
Percent reduction vs placebo 34.58 30.82
Complex partial (focal impaired awareness), nb 98 109 99 109
Baseline seizure frequency per 28 d, median 7.50 8.30 7.50 8.30
Seizure frequency per 28 d during assessed trial period, mediana 8.19 4.67 8.11 5.45
Percent reduction vs placebo 34.67 32.41
Partial evolving to secondarily generalized (focal to bilateral
tonic-clonic), nb
69 63 69 63
Baseline seizure frequency per 28 d, median 5.31 4.50 5.31 4.50
Seizure frequency per 28 d during assessed trial period, mediana 2.43 2.21 3.68 2.73
Percent reduction vs placebo 19.75 23.35
Complex partial/secondarily generalized, nb 133 139 134 139
Baseline seizure frequency per 28 d, median 8.00 8.50 8.00 8.50
Seizure frequency per 28 d during assessed trial period, mediana 7.20 4.00 8.14 5.14
Percent reduction vs placebo 28.14 27.2









Focal seizures, n 106 115 107 115
Baseline seizure frequency per 28 d, median 9.00 15.00 9.00 15.00
Seizure frequency per 28 d during assessed trial period, mediana 7.20 7.60 7.93 7.59
Percent reduction vs placebo 31.43 28.19









Focal seizures, n 62 55 62 55
Baseline seizure frequency per 28 d, median 8.25 8.81 8.25 8.81
Seizure frequency per 28 d during assessed trial period,
mediana
12.15 3.25 11.86 4.75
Percent reduction vs placebo 32.38 33.87
Abbreviations: CI = confidence interval; SCB AED = sodium channel–blocking antiepileptic drug.
a Maintenance or treatment period.
b Seizure types are listed per the trial protocol (International League Against Epilepsy [ILAE] 1981)21 with the ILAE 2017 classification22 provided in
parentheses.
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lacosamide (placebo: 8 [4.7%]). All events of somnolence
were mild or moderate in intensity. One patient discontinued
lacosamide due to somnolence. The median time from laco-
samide initiation to onset of somnolence was 24.0 days
(placebo 6.0 days), with a median dose at somnolence onset
of 8.0 mg/kg/d among patients in the <30 kg and 30 to <50 kg
weight bands and 225 mg/d among patients weighing ≥50 kg.
The median duration of somnolence during treatment was 6.0
days on lacosamide and 9.5 days on placebo.
Eighteen (10.5%) patients on lacosamide reported a total of
22 events of dizziness (placebo 6 [3.5%] patients, 6 events).
Dizziness was considered to be drug related in 15 (8.8%)
patients on lacosamide and 4 (2.3%) on placebo. All events
were mild to moderate in intensity, and none led to trial
discontinuation. The median time from lacosamide initiation
to onset of dizziness was 26.5 days (placebo 38.5 days), with
a median dose at onset of 6.0 mg/kg/d for patients weighing
30 to <50 kg and 350 mg/d for patients weighing ≥50 kg. The
median duration of dizziness during treatment was 7.5 days on
lacosamide and 12.5 days on placebo.
Psychiatric TEAEs were reported by 11 (6.4%) patients in
each treatment group. Insomnia was the most common psy-
chiatric TEAE, reported by 4 (2.3%) patients on lacosamide
and 2 (1.2%) patients on placebo (table 3). Two patients
(1.2%) treated with lacosamide had a total of 3 events of
suicidal ideation. These events were mild in intensity, were
resolved, and were not related to trial medication as assessed
by the trial investigator. There were no suicide attempts
during the trial. Severe psychiatric TEAEs were reported by 1
patient on placebo only (severe auditory hallucinations). No
patients reported TEAEs related to psychotic disorders,
memory impairment, amnesia, or cognitive disorders.
Similar incidences of serious TEAEs were observed in patients
on lacosamide (8 [4.7%]) and placebo (10 [5.8%]), and none
were considered to be drug-related (table 3). Convulsionwas the
only serious TEAE reported by ≥2 patients (lacosamide: 2
[1.2%]; placebo: 3 [1.7%]). A serious TEAE of syncope was
reported by 1 patientwhile on a dose of 5.5mg/kg/d lacosamide.
This TEAE was moderate in intensity, did not lead to a dose
change, and resolved. The patient experienced a secondTEAEof
Figure 3 Analyses of focal seizure frequency per 28 days during maintenance
(A) Median percent reduction from baseline, (B) 50% responder rates, and (C) 75% responder rates, assessed for the overall population and for patients with
and without concomitant sodium channel–blocking antiepileptic drugs (SCB AEDs). **p ≤ 0.01, ***p ≤ 0.001.
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syncope 6 days after her final lacosamide dose; this TEAE was
considered to be serious but mild in intensity. Neither incident
was considered to be related to lacosamide. ECG data showed
a slight prolongation of the PR duration andQRS duration (table
e-1 available from Dryad, doi.org/10.5061/dryad.kt5jj49). One
patient had a serious TEAE of bradycardia while on a dose of 8
mg/kg/d lacosamide; this TEAE was mild in intensity, was not
considered to be related to lacosamide, did not lead to a dose
change, and resolved. Vital signs assessments before treatment
(screening and baseline visits) showed that the patient had
a supine pulse rate of 82 to 84 bpm. All supine pulse rates
recorded at vital signs assessments during treatment were ≥66
bpm, except for the value recorded during the event of brady-
cardia (61 bpm). None of the patient’s ECG parameters showed
Table 3 TEAEs during the titration, maintenance, and treatment periods (safety set)
Patients, n (%)
















Any TEAEs, n (%) 78 (45.3) 96 (56.1) 53 (32.9) 71 (44.1) 100
(58.1)
116 (67.8)
Drug-related TEAEs 28 (16.3) 50 (29.2) 8 (5.0) 17 (10.6) 31 (18.0) 54 (31.6)
Serious TEAEs 4 (2.3) 5 (2.9) 7 (4.3) 4 (2.5) 10 (5.8) 8 (4.7)
Drug-related serious TEAEs 0 0 0 0 0 0
Severe TEAEs 3 (1.7) 5 (2.9) 3 (1.9) 1 (0.6) 6 (3.5) 5 (2.9)
Discontinuations due to TEAEs 8 (4.7) 6 (3.5) 3 (1.9) 1 (0.6) 10 (5.8) 7 (4.1)
Deaths 0 0 0 0 0 0
TEAEs reported by ≥5% of patients in either treatment group
during the treatment period, n (%)
Somnolence 9 (5.2) 20 (11.7) 0 5 (3.1) 9 (5.2) 24 (14.0)
Dizziness 4 (2.3) 17 (9.9) 2 (1.2) 2 (1.2) 6 (3.5) 18 (10.5)
Nasopharyngitis 6 (3.5) 13 (7.6) 1 (0.6) 6 (3.7) 7 (4.1) 17 (9.9)
Vomiting 4 (2.3) 10 (5.8) 3 (1.9) 7 (4.3) 7 (4.1) 15 (8.8)
Pyrexia 3 (1.7) 9 (5.3) 4 (2.5) 6 (3.7) 7 (4.1) 14 (8.2)
Headache 7 (4.1) 8 (4.7) 7 (4.3) 4 (2.5) 11 (6.4) 11 (6.4)
Upper respiratory tract infection 5 (2.9) 6 (3.5) 6 (3.7) 3 (1.9) 10 (5.8) 8 (4.7)
Psychiatric TEAEs reported by ≥1% of patients in either
treatment group during the treatment period, n (%)
Insomnia 2 (1.2) 2 (1.2) 1 (0.6) 2 (1.2) 2 (1.2) 4 (2.3)
Sleep disorder 0 2 (1.2) 0 0 0 2 (1.2)
Suicidal ideation 0 2 (1.2) 0 1 (0.6) 0 2 (1.2)
Aggression 2 (1.2) 0 0 0 2 (1.2) 0
Emotional disorder 2 (1.2) 0 0 0 2 (1.2) 0
TEAEs leading to discontinuation in ≥1% of patients in either
treatment group during the treatment period, n (%)
Vertigo 0 2 (1.2) 0 0 0 2 (1.2)
Diplopia 0 1 (0.6) 0 1 (0.6) 0 2 (1.2)
Increased alanine aminotransferase 2 (1.2) 1 (0.6) 0 0 2 (1.2) 1 (0.6)
Increased aspartate aminotransferase 2 (1.2) 0 0 0 2 (1.2) 0
Abbreviation: TEAE = treatment-emergent adverse event.
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a clear increase during treatment, and most recordings showed
a shortened PR duration compared to baseline (table e-2 avail-
able from Dryad, doi.org/10.5061/dryad.kt5jj49).
Few patients in either treatment group (lacosamide 7 [4.1%];
placebo 10 [5.8%]) had a TEAE that led to discontinuation
during the treatment period (table 3). Discontinuation due to
TEAEs was more common during titration than maintenance
(table 3), with a median time to discontinuation of 36 days in
the lacosamide group and 50 days in the placebo group.
Vertigo and diplopia were the only TEAEs leading to dis-
continuation of lacosamide in ≥2 patients (diplopia [n = 1];
vertigo [n = 1]; vertigo and diplopia [n = 1]; these events were
considered drug related), all of whom were receiving con-
comitant treatment with a SCB AED.
Analyses of tolerability by number of concomitant AEDs did
not show any clear trends in the overall incidences of TEAEs,
drug-related TEAEs, or discontinuations due to TEAEs (table
e-3 available from Dryad, doi.org/10.5061/dryad.kt5jj49).
Similar incidences of somnolence were observed in
lacosamide-treated patients on 1, 2, or 3 concomitant AEDs,
whereas the majority of patients who reported somnolence on
placebo were taking 3 concomitant AEDs. The incidence of
dizziness on lacosamide appeared to increase with an in-
creasing number of concomitant AEDs.
Analyses by concomitant SCB use showed a higher incidence
of drug-related TEAEs in patients taking lacosamide with
a concomitant SCB (34.5%; 16.7% with placebo) than in
those with no SCB AEDs (25.5%; 20.3% with placebo) (table
4). The incidence of drug-related somnolence was similar in
lacosamide-treated patients who were on and those not on
concomitant SCB AEDs, whereas the incidence of drug-
related dizziness was higher in lacosamide-treated patients
who were on concomitant SCBs than in those not on SCB
AEDs. Discontinuations due to TEAEs were low in
lacosamide-treated patients and were similar to those of
patients taking placebo regardless of whether SCB AEDs were
part of the treatment regimen (on concomitant SCBs: 5.2%
with lacosamide, 6.5% with placebo; not on SCB AEDs: 1.8%
with lacosamide, 4.7% with placebo).
Assessments of behavior and cognitive function showed
stable scores over the treatment period. Shifts from baseline
to last visit in Achenbach CBCL 1.5—5 and CBCL/6—18
T-scores were similar in patients on lacosamide and on
placebo (table e-4 available from Dryad, doi.org/10.5061/
dryad.kt5jj49), with most patients remaining in their base-
line category (normal, borderline, or clinically significant).
Of those with a change in category, more improved than
worsened. For the BRIEF and BRIEF-Preschool assess-
ments, shifts in T-score findings from baseline to last visit
were similar in each treatment group, with very few patients
changing category (table e-5 available from Dryad, doi.org/
10.5061/dryad.kt5jj49). Of those with a change in category,
more patients improved than worsened.
No consistent or clinically relevant changes from baseline
were observed for hematology, clinical chemistry, or endo-
crinology parameters, and no clinically relevant changes were
observed for vital signs or ECG assessments. Pharmacokinetic
data for lacosamide are shown in table e-6 (available from
Dryad, doi.org/10.5061/dryad.kt5jj49). For patients on
lacosamide, the geometric LS mean ratios for treatment/
baseline and their 90% CIs were within the 80% to 125%
limits for valproic acid, levetiracetam, lamotrigine, carbama-
zepine, topiramate, and oxcarbazepine (MHD) (figure e-3
available from Dryad, doi.org/10.5061/dryad.kt5jj49).
Discussion
In this double-blind placebo-controlled trial, adjunctive
lacosamide was efficacious in reducing seizure frequency and
was generally well tolerated in children and adolescents (age
≥4–<17 years) with uncontrolled focal seizures.
A weight-based dosing scheme was used; the maximum dose
for each weight band targeted plasma levels shown to be at the
upper limit of the therapeutic adjunctive dose in adults (400
mg/d).23 This weight-based dosing algorithm and flexible
dose escalation during the titration period allowed physicians
to tailor lacosamide treatment for each child.
A clinically relevant, significant reduction in focal seizure
frequency per 28 days was observed with lacosamide vs
placebo from baseline to the maintenance and treatment
periods. Secondary and post hoc analyses showed greater
median percent reductions from baseline in focal seizure
frequency, as well as higher 50% and 75% responder rates
and higher seizure-freedom rates, with lacosamide compared
with placebo. Lacosamide was efficacious regardless of
whether SCB AEDs were part of the concomitant treatment
regimen. Subgroup analyses indicated the efficacy of laco-
samide across all focal seizure types. The efficacy of lacosa-
mide observed in children and adolescents in the current
trial was in line with that reported for adults with focal
seizures.4–6,24 These results further support the concept of
extrapolation of efficacy data from adults to the pediatric
population with focal seizures.25
The 50% responder rate observed with lacosamide in chil-
dren (52.9%) was consistent with that reported for adults
(35%–49%); however, the 50% responder rate with placebo
was somewhat higher (33.3% vs 22.6%).24 This was not
unexpected because higher 50% responder rates for placebo
have been observed in children compared with adults.26 In
this trial, the 50% responder rate with placebo was compa-
rable to that reported with placebo in a randomized trial of
adjunctive zonisamide in children with focal seizures
(31%).27
The TEAEs most commonly reported during adjunctive
lacosamide treatment in children were consistent with AEs
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Table 4 TEAEs during the titration, maintenance, and treatment periods by concomitant SCB AED use (safety set)
Patients
With ≥1 SCB AED, n (%) Without SCB AEDs, n (%)

























Any TEAEs 51 (47.2) 60 (51.7) 34 (33.3) 47 (43.5) 64 (59.3) 74 (63.8) 27 (42.2) 36 (65.5) 19 (32.2) 24 (45.3) 36 (56.3) 42 (76.4)
Drug-related TEAEs 15 (13.9) 36 (31.0) 6 (5.9) 15 (13.9) 18 (16.7) 40 (34.5) 13 (20.3) 14 (25.5) 2 (3.4) 2 (3.8) 13 (20.3) 14 (25.5)
Serious TEAEs 3 (2.8) 3 (2.6) 5 (4.9) 3 (2.8) 7 (6.5) 5 (4.3) 1 (1.6) 2 (3.6) 2 (3.4) 1 (1.9) 3 (4.7) 3 (5.5)
Discontinuations due to TEAEs 5 (4.6) 5 (4.3) 3 (2.9) 1 (0.9) 7 (6.5) 6 (5.2) 3 (4.7) 1 (1.8) 0 0 3 (4.7) 1 (1.8)
Drug-related TEAEs reported by ≥5% of
patients in any treatment subgroup
during the treatment period, n (%)
Somnolence 4 (3.7) 13 (11.2) 0 2 (1.9) 4 (3.7) 15 (12.9) 4 (6.3) 5 (9.1) 0 1 (1.9) 4 (6.3) 6 (10.9)
Dizziness 2 (1.9) 11 (9.5) 1 (1.0) 2 (1.9) 3 (2.8) 12 (10.3) 1 (1.6) 3 (5.5) 0 0 1 (1.6) 3 (5.5)
Vomiting 1 (0.9) 5 (4.3) 0 2 (1.9) 1 (0.9) 6 (5.2) 1 (1.6) 1 (1.8) 0 0 1 (1.6) 1 (1.8)
Diplopia 0 7 (6.0) 0 2 (1.9) 0 7 (6.0) 0 0 0 0 0 0





















reported during lacosamide treatment in adults (somno-
lence, dizziness) and with infections frequently encoun-
tered in double-blind placebo-controlled trials and open-
label studies of other AEDs in pediatric patients with focal
seizures (nasopharyngitis, pyrexia).27–33 The incidences of
nasopharyngitis and pyrexia were higher with lacosamide
than placebo; however, these TEAEs mainly occurred dur-
ing the titration period, with low incidences (<4% of
patients) during maintenance. A similar proportion of
patients on lacosamide and placebo reported psychiatric
TEAEs. The incidence of serious TEAEs was similar on
lacosamide and placebo, and few patients in both treatment
groups reported severe TEAEs or discontinued because of
TEAEs. In both treatment groups, a higher incidence of
TEAEs was reported during titration than maintenance,
which is consistent with data reported in adults.34 This
difference was most pronounced for drug-related TEAEs,
with 29% of patients on lacosamide reporting TEAEs in this
category during titration vs 11% during maintenance.
However, the initiation and flexible uptitration of lacosa-
mide was generally well tolerated with few patients re-
quiring a dose reduction or discontinuing because of
TEAEs. In both treatment groups, analyses of tolerability by
number of concomitant AEDs did not show any trends in
the overall incidences of TEAEs, drug-related TEAEs, or
discontinuations because of TEAEs.
Somnolence and dizziness were the most commonly
reported TEAEs, and the most common drug-related
TEAEs during adjunctive lacosamide treatment. Somno-
lence and dizziness occurred mainly during titration, and the
duration of these TEAEs was similar between patients on
lacosamide and those on placebo. In the lacosamide group,
the incidence of somnolence was not related to the number
of concomitant AEDs. Drug-related somnolence was
reported by similar proportions of patients treated with
lacosamide on concomitant SCB AEDs (12.9%) and those
not on SCB AEDs (10.9%). The incidence of dizziness with
lacosamide increased with the number of concomitant
AEDs, and the incidence of drug-related dizziness was higher
in patients on SCB AEDs (10.3%) than in those not on SCB
AEDs (5.5%).
Clinical practice experience with adjunctive lacosamide has
shown a better35–38 or similar39–41 tolerability profile in
adult patients not on SCB AEDs compared with those on
SCB AEDs. A retrospective cohort study of children and
adolescents (age <21 years) with focal, generalized, or
mixed epilepsy (n = 223) showed that use of an SCB AED
was an independent predictor of time to lacosamide
treatment failure.42 Furthermore, analyses of pooled data
from double-blind placebo-controlled trials in adults
showed a potential for better tolerability of adjunctive
lacosamide when taken without SCB AEDs.43 Among
lacosamide-treated adults on a SCB AED, discontinuations
because of AEs were dose-dependent (200 mg, 5.5%;
400 mg, 14.4%; 600 mg, 31.0%) and most commonly
occurred because of dizziness (7.0% of patients).43 In
contrast, adjunctive lacosamide was well tolerated in the
current pediatric trial regardless of whether SCB AEDs
were part of the treatment regimen. Discontinuation rates
were similar for lacosamide and placebo in patients with
and without concomitant SCB AEDs, and no patients dis-
continued because of dizziness. The improved tolerability
of adjunctive lacosamide in patients on SCB AEDs in the
pediatric trial compared to the trials in adults may be re-
lated to the different trial designs. The pediatric trial had
a flexible titration schedule with the option of back-titration
steps if needed, whereas the adult trials applied forced ti-
tration to a predefined randomized dose for each patient.
Individualized titration and dosing may allow optimization
of tolerability of adjunctive lacosamide treatment in
patients taking various AED combinations.
Children with epilepsy have an increased risk for several
neurologic (e.g., cognitive impairment) and psychological
(e.g., mood disorders, attention-deficit/hyperactivity disor-
der) disorders, some of which may be linked to the use of
AEDs.44 The presence of hyperactivity or impulsivity at the
time of AED treatment initiation is a predictor of behavioral
side effects.45 In the current trial, scores for behavior and
cognitive function (Achenbach CBCL and BRIEF) were
generally stable and similar for both treatment groups, with
no worsening for patients on lacosamide vs placebo; how-
ever, results for the 4- to 6-year-old group should be inter-
preted with caution given the small number of patients in
this category. Further evaluations are needed to determine
the long-term effects of lacosamide on cognition and be-
havior in children.
In children and adolescents (age ≥4–<17 years) with focal
seizures, plasma concentrations of valproic acid, levetir-
acetam, lamotrigine, carbamazepine, topiramate, oxcarba-
zepine (MHD), clonazepam, and clobazam were not
affected by concomitant lacosamide use. The data for clo-
nazepam and clobazam should be interpreted with caution
because of the small sample size. In line with data in adults,46
these pharmacokinetic analyses suggest that no dose ad-
justment for the respective AEDs would generally be needed
when lacosamide is added to or removed from the treatment
regimen.
In this randomized double-blind trial, adjunctive lacosa-
mide was efficacious in reducing focal seizure frequency in
children and adolescents (≥4 to <17 years of age) with
uncontrolled focal seizures and was generally well tolerated
with flexible titration and weight-based dosing. These data,
together with the favorable, predictable pharmacokinetic
profile of lacosamide, its low potential for clinically relevant
pharmacokinetic drug-drug interactions, and bioequivalent
oral (tablets or oral solution) formulations,3,47 demon-
strate that lacosamide is a valuable addition to the arma-
mentarium of licensed therapies for focal seizures in
pediatric patients.
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